Professor Arden Rowell, in conjunction with researchers from the University of Illinois Grainger College of Engineering, recently published an article in Nuclear News proposing an interdisciplinary framework for modernizing one of the foundational principles of radiation protection. The U.S. Nuclear Regulatory Commission (NRC) recently released a proposed rule that would remove the long-standing As Low As Reasonably Achievable (ALARA) principle from its radiation protection regulations while retaining existing dose limits and opening the proposal for public comment, making their article, “Don’t Scrap ALARA—Modernize It,” especially timely.

In an new essay on Health Affairs, Professor Jacob Sherkow writes that the U.S. Supreme Court made the correct decision in Hikma Pharmaceuticals v. Amarin Pharma, giving generic drug manufacturers important protection against patent suits based on labeling approved by the Food and Drug Administration (FDA). This decision will “help preserve patient access to lower-cost medicines,” he writes; however, it also shifts pressure onto FDA, which does not interpret patent claims or decide whether future prescribing will infringe.

In June, Professor Sarah Lawsky joined a panel discussion on Turning Law into Verified Code at the Federal Reserve Bank of New York’s Innovation Conference. The two-day conference brought together individuals from academia, industry, and other areas to share ideas on technology and finance. The conference explored the landscape of the financial world and the role of banks and the private sector in innovation and stability.

Faculty and researchers from the University of Illinois Urbana-Champaign have submitted a public comment to the U.S. Nuclear Regulatory Commission (NRC) addressing the agency’s proposed rule on “Part 57,” a major regulatory initiative that attempts to modernize U.S. nuclear regulation by creating a dedicated licensing framework for new nuclear technologies, including microreactors and certain advanced nuclear reactors.

When a law is inconsistent, further guidance should come from Congress, courts, and administrative agencies to create clarity. In her recent article, Professor Sarah Lawsky examines via a programming language framework an example of a tax statute that mandates inconsistent outcomes for the same set of facts and shows how that inconsistency has been addressed by the Treasury and the IRS. Her article was also the subject of a TaxProfBlog article, which you can read online.

In order to bring a drug to market, manufacturers have long been required to demonstrate safety and effectiveness in clinical trials; however, Health and Human Services Secretary Robert F. Kennedy Jr. would like to change the Food and Drug Administration’s role to make it easier access experimental medicine. In an article on the FDA considering allowing pharmacies to compound and sell seven unapproved peptides, Undark quoted Professor Jacob Sherkow who called this “a brave new world” in which some substances may “go forward without any rigorous scientific evidence base.”

Direct File, a program that allows some taxpayers to file federal income tax returns with the United States government online for free, is an extraordinary accomplishment, Professor Sarah Lawsky writes in a new article published in the Pittsburgh Tax Review. Examining the computer code underlying Direct File, Lawsky finds choices that make “the application of the law and various administrative choices more transparent even to those who are not comfortable reading computer code.”

On Monday, June 1, Professor Jacob Sherkow will deliver a lecture at the 15th Waseda-Penn Global Patent Law Conference in Japan. His talk will introduce the fundamentals of indirect patent infringement under U.S. law, with a focus on inducement doctrine under 35 U.S.C. § 271(b). Drawing on recent litigation and scholarship — including the “infringement by label” debate highlighted in the Supreme Court case Hikma v. Amarin — the talk will critically examine how current case law risks expanding inducement liability beyond its traditional requirement of active encouragement and causation. In doing so, the lecture will highlight broader questions about the proper limits of indirect infringement and the role of regulatory contexts in shaping liability—issues that also resonate in ongoing Japanese debates on the scope and structure of secondary patent liability.

In a new co-authored article for Nature Reviews Gastroenterology & Hepatology, Professor Sara Gerke explores the risks of “deskilling” for physicians as the use of AI proliferates in the practice of medicine. Gerke and her co-authors also explore whether such systems violate the European Union Artificial Intelligence Act, the world’s first comprehensive regulatory framework on artificial intelligence.

A first-of-its-kind pilot program in Utah developed by a health-technology startup company uses artificial intelligence to automatically renew certain prescriptions for patients with chronic conditions such as hypertension and diabetes. But according to a new paper co-written by a University of Illinois Urbana-Champaign expert in legal issues surrounding cutting-edge medical technology, autonomous AI-based drug prescribing raises important clinical and legal issues.